secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cryoport, Inc. (CYRX)
CIK:        0001124524
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001104659-25-074314
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cryoport Q2 revenue up 14% to $45.5M; cell & gene therapy revenue +33%; reaffirms FY25 guidance
--------------------------------------------------------------------------------

- Net income of $105.2M includes $117.4M gain from CRYOPDP divestiture; adjusted EBITDA improved to -$0.9M vs -$5.6M a year ago.
- Life Sciences Services revenue grew 21% to $24.4M (54% of total); BioStorage/BioServices up 28%.
- Commercial cell & gene therapy revenue rose 33% to $8.7M; supported 18 commercial therapies and 728 global trials.
- Closed strategic partnership with DHL and divestiture of CRYOPDP on June 11, 2025; cash & investments $426M.
- Reaffirmed FY2025 revenue guidance of $165M–$172M, representing 5%-10% YoY growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124524/000110465925074314/0001104659-25-074314-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124524/000110465925074314/tm2522626d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-074314

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer